Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

NCT00436254 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Stage III Ovarian Epithelial Cancer
Stage III Ovarian Germ Cell Tumor
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Stage IV Ovarian Epithelial Cancer
Stage IV Ovarian Germ Cell Tumor

Interventions

BIOLOGICAL: pNGVL3-hICD vaccine
BIOLOGICAL: sargramostim
OTHER: flow cytometry
OTHER: immunologic technique
OTHER: immunoenzyme technique
GENETIC: protein expression analysis
PROCEDURE: biopsy

Sponsor

University of Washington

Collaborators

[object Object]